LEO Applies to EMA to Expand Anzupgo Use to Adolescents

LEO applies to EMA to expand Anzupgo use to adolescents

LEO Pharma has applied to the EMA to expand the label for Anzupgo (delgocitinib) cream to include adolescents.

LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA

LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase [...] The post LEO Pharma Submits Adolescent Label Expansion Application for Anzup…